Multiple Myeloma Clinical Trial
Official title:
Identification of Hematological Malignancies and Therapy Predication Using microRNAs as a Diagnostic Tool
MiRNAs are small (~19-25 nucleotides) non-coding RNA molecules that bind to mRNA in a
sequence-specific manner. MiRNAs regulate gene expression at the post-transcriptional level.
MiRNAs regulate critical cell processes such as metabolism, apoptosis, development, cell
cycle, hematopoietic differentiation and have been implicated in the development and
progression of several types of cancers, including hematological malignancies.
Over-expression, amplification and/or deletion of miRNAs and miRNA-mediated modification of
epigenetic silencing can all lead to oncogenic pathways.
Hematologic cancers, which are caused by the malignant transformation of bone marrow cells
and the lymphatic system, are usually divided into three major clusters: leukemia, lymphoma,
and multiple myeloma. To date, some of the hematological malignancies are very aggressive
that early diagnosis is essential for improving prognosis and increasing survival rates.
However, current diagnostic methods have various limitations, such as insufficient
sensitivity, specificity, it is also time-consuming, costly, and requires a high level of
expertise, which limits its application in clinical contexts. Thus, development of new
biomarkers for the early detection and relapse of hematological malignancies is desirable.
Some of the innate properties of miRNAs make them highly attractive as potential biomarkers.
MiRNAs can be readily detected in small volume samples using specific and sensitive
quantitative real-time PCR; they have been isolated from most body fluids, including serum,
plasma, urine, saliva, tears and semen and are known to circulate in a highly stable,
cell-free form. They are highly conserved between species, allowing the use of animal models
of disease for pre-clinical studies. Furthermore, tumor cells have been shown to release
miRNAs into the circulation and profiles of miRNAs are altered in the plasma and/or serum of
patients with cancer. A growing number of publications confirm that miRNAs can be a useful
biomarker for hematological malignancies diagnosis and progression.
n/a
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05027594 -
Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
| Completed |
NCT02412878 -
Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma
|
Phase 3 | |
| Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05971056 -
Providing Cancer Care Closer to Home for Patients With Multiple Myeloma
|
N/A | |
| Recruiting |
NCT05243797 -
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
|
Phase 3 | |
| Active, not recruiting |
NCT04555551 -
MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma
|
Phase 1 | |
| Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
| Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
| Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
| Completed |
NCT02916979 -
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
|
Phase 1 | |
| Recruiting |
NCT03570983 -
A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion
|
Phase 2 | |
| Terminated |
NCT03399448 -
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
|
Phase 1 | |
| Completed |
NCT03665155 -
First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody
|
Phase 1/Phase 2 | |
| Completed |
NCT02812706 -
Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05024045 -
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
|
Phase 1 | |
| Active, not recruiting |
NCT03792763 -
Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients
|
Phase 2 | |
| Active, not recruiting |
NCT03989414 -
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT03608501 -
A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation
|
Phase 2 | |
| Recruiting |
NCT04537442 -
Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
| Completed |
NCT02546167 -
CART-BCMA Cells for Multiple Myeloma
|
Phase 1 |